October 28, 2016 7:56 AM ET

Healthcare Equipment and Supplies

Company Overview of AxoGen, Inc.

Company Overview

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf human nerve allograft for bridging nerve discontinuities without the comorbidities associated with another surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue atta...

13631 Progress Boulevard

Suite 400

Alachua, FL 32615

United States

113 Employees





Key Executives for AxoGen, Inc.

Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $511.0K
Senior Vice President of Business Development, General Counsel and Director
Age: 54
Total Annual Compensation: $303.0K
Senior Vice President of Sales
Age: 58
Total Annual Compensation: $374.3K
Compensation as of Fiscal Year 2015.

AxoGen, Inc. Key Developments

AxoGen, Inc. Announces Refinancing of Debt Facility

AxoGen, Inc. announced that it has completed the refinancing of its existing debt agreement with a new facility from MidCap Financial. The new facility consists of a $21.0 million term loan and a $10.0 million revolving line of credit, of which $4.0 million has been drawn. The revolving line of credit may be increased up to $15 million at a later date at the company’s request and with approval of Midcap. The facility carries a 54-month term with interest only payments on the term loan for the first 24 months.  The interest rate on the term loan is 8.0% plus the greater of LIBOR or 0.5%, which at the closing resulted in a rate of 8.5%.  Borrowings under the revolving line of credit bear interest of 4.5% plus the greater of LIBOR or 0.5% which, at the closing resulted in a rate of 5.0%.  The company estimates annual interest cost savings of the new facility will be at least $1.5 million compared to the previous debt facility.  The facility requires the company to maintain certain minimum net revenue requirements. Proceeds from this financing were used to repay and retire the company’s existing $25.0 million term loan and revenue royalty interest agreement with Three Peaks Capital S.a.r.l, an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund, LP.

AxoGen, Inc. Announces Board Changes

On September 16, 2016, Joseph Mandato submitted to AxoGen, Inc. his letter of resignation as a member of the Board of Directors of the Company, effective immediately. The Board accepted Mr. Mandatos letter of resignation. The company notes that Mr. Mandatos resignation was not the result of any disagreement with the company relating to the company's operations, policies or practices. Mr. Mandato served on the AxoGen Corporation (AC) board of directors from February 2006 until ACs merger with and into the company in September 2011, and served on the Board since such merger. Mr. Mandato has served on the company's Governance and Nominating Committee since December 2015. Based on the recommendation of, and nomination by, the company's Governance and Nominating Committee, Amy Wendell was appointed to the Board to fill the vacancy on the Board resulting from Mr. Mandatos resignation, effective September 16, 2016. Additionally, as a result of Mr. Mandatos resignation, the Board reviewed the composition of its committees and determined to have Ms. Wendell appointed to the Governance and Nominating and Compensation Committee, effective September 16, 2016. Ms. Wendell, age 55, has been a senior advisor for Perella Weinberg Partners (PWP) healthcare investment banking practice since January 2016. Her scope of responsibilities involves providing guidance and advice with respect to mergers and acquisitions and divestitures for clients, and assisting PWP in connection with firm-level transactions. Since 2015, Ms. Wendell has also been a senior advisor for McKinsey and company's strategy and corporate finance practice and also serves as a member of McKinsey's transactions advisory board to help define trends in mergers and acquisitions, as well as help shape McKinsey's knowledge agenda.

AxoGen, Inc.(NasdaqCM:AXGN) added to S&P Global BMI Index

AxoGen, Inc.(NasdaqCM:AXGN) added to S&P Global BMI Index

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AxoGen, Inc., please visit www.axogeninc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.